JP7451543B2 - Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 - Google Patents

Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 Download PDF

Info

Publication number
JP7451543B2
JP7451543B2 JP2021546360A JP2021546360A JP7451543B2 JP 7451543 B2 JP7451543 B2 JP 7451543B2 JP 2021546360 A JP2021546360 A JP 2021546360A JP 2021546360 A JP2021546360 A JP 2021546360A JP 7451543 B2 JP7451543 B2 JP 7451543B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
refers
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519744A5 (https=
JP2022519744A (ja
JPWO2020163268A5 (https=
Inventor
セカレシュ，ヘレン，ジェーン
ワットン，マリア，アン
ウィリアムズ，アンドリュ，カウェールウィン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2022519744A publication Critical patent/JP2022519744A/ja
Publication of JP2022519744A5 publication Critical patent/JP2022519744A5/ja
Publication of JPWO2020163268A5 publication Critical patent/JPWO2020163268A5/ja
Priority to JP2024033668A priority Critical patent/JP2024063191A/ja
Application granted granted Critical
Publication of JP7451543B2 publication Critical patent/JP7451543B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021546360A 2019-02-06 2020-02-04 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 Active JP7451543B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024033668A JP2024063191A (ja) 2019-02-06 2024-03-06 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962801716P 2019-02-06 2019-02-06
US62/801,716 2019-02-06
US201962811038P 2019-02-27 2019-02-27
US62/811,038 2019-02-27
PCT/US2020/016499 WO2020163268A1 (en) 2019-02-06 2020-02-04 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024033668A Division JP2024063191A (ja) 2019-02-06 2024-03-06 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体

Publications (4)

Publication Number Publication Date
JP2022519744A JP2022519744A (ja) 2022-03-24
JP2022519744A5 JP2022519744A5 (https=) 2023-02-13
JPWO2020163268A5 JPWO2020163268A5 (https=) 2023-02-13
JP7451543B2 true JP7451543B2 (ja) 2024-03-18

Family

ID=69743945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546360A Active JP7451543B2 (ja) 2019-02-06 2020-02-04 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体
JP2024033668A Withdrawn JP2024063191A (ja) 2019-02-06 2024-03-06 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024033668A Withdrawn JP2024063191A (ja) 2019-02-06 2024-03-06 Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体

Country Status (23)

Country Link
US (4) US11208383B2 (https=)
EP (1) EP3921030B1 (https=)
JP (2) JP7451543B2 (https=)
KR (1) KR102924196B1 (https=)
CN (1) CN113692304B (https=)
AU (1) AU2020218180B2 (https=)
BR (1) BR112021015544A2 (https=)
DK (1) DK3921030T3 (https=)
ES (1) ES2968807T3 (https=)
FI (1) FI3921030T3 (https=)
HR (1) HRP20240012T1 (https=)
HU (1) HUE064734T2 (https=)
IL (1) IL285113B2 (https=)
LT (1) LT3921030T (https=)
MX (1) MX2021009396A (https=)
PL (1) PL3921030T3 (https=)
PT (1) PT3921030T (https=)
RS (1) RS65040B1 (https=)
SA (1) SA521422733B1 (https=)
SG (1) SG11202108599SA (https=)
SI (1) SI3921030T1 (https=)
SM (1) SMT202400003T1 (https=)
WO (1) WO2020163268A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064734T2 (hu) * 2019-02-06 2024-04-28 Lilly Co Eli 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok
CA3183298A1 (en) 2020-06-25 2021-12-30 Olivier Bezencon Cyclobutyl-urea derivatives
TW202330471A (zh) * 2021-09-30 2023-08-01 日商住友製藥股份有限公司 環丙醯胺衍生物
WO2023091554A1 (en) * 2021-11-19 2023-05-25 Icagen, Llc Novel heteroaryl-urea compounds as kv7.2 inhibitors
EP4433472A1 (en) 2021-11-19 2024-09-25 Icagen, LLC Pyridine compounds as kv7.2 enhancers
JP2025502712A (ja) 2021-12-22 2025-01-28 アイカジェン・エルエルシー シクロプロピル化合物
EP4479377A1 (en) 2022-02-15 2024-12-25 Icagen, LLC New bicyclopentane derivatives
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
WO2016063990A1 (ja) 2014-10-24 2016-04-28 小野薬品工業株式会社 Ｋｃｎｑ２～５チャネル活性化剤
JP2016516724A (ja) 2013-03-15 2016-06-09 デシフェラ ファーマシューティカルズ，エルエルシー 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体
JP2017507951A (ja) 2014-02-27 2017-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用
WO2017183723A1 (ja) 2016-04-22 2017-10-26 小野薬品工業株式会社 Ｋｃｎｑ２～５チャネル活性化剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL335905A1 (en) * 1997-03-25 2000-05-22 Astra Pharma Prod Novel derivatives of pyridine and pharmaceutic compositions containing them
CN100345823C (zh) * 2003-01-14 2007-10-31 赛特凯恩蒂克公司 化合物、组合物及方法
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
US7879839B2 (en) * 2004-07-29 2011-02-01 Merck Sharp & Dohme Corp. Potassium channel inhibitors
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
EP2681200A4 (en) * 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
HUE064734T2 (hu) * 2019-02-06 2024-04-28 Lilly Co Eli 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
JP2016516724A (ja) 2013-03-15 2016-06-09 デシフェラ ファーマシューティカルズ，エルエルシー 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体
JP2017507951A (ja) 2014-02-27 2017-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用
WO2016063990A1 (ja) 2014-10-24 2016-04-28 小野薬品工業株式会社 Ｋｃｎｑ２～５チャネル活性化剤
WO2017183723A1 (ja) 2016-04-22 2017-10-26 小野薬品工業株式会社 Ｋｃｎｑ２～５チャネル活性化剤

Also Published As

Publication number Publication date
KR20210126040A (ko) 2021-10-19
BR112021015544A2 (pt) 2021-10-26
US11208383B2 (en) 2021-12-28
IL285113B2 (en) 2025-10-01
CN113692304B (zh) 2025-03-18
PT3921030T (pt) 2024-01-12
IL285113B1 (en) 2025-06-01
HRP20240012T1 (hr) 2024-03-29
US20250282725A1 (en) 2025-09-11
HUE064734T2 (hu) 2024-04-28
JP2024063191A (ja) 2024-05-10
US20220073464A1 (en) 2022-03-10
LT3921030T (lt) 2024-01-25
EP3921030A1 (en) 2021-12-15
CN113692304A (zh) 2021-11-23
AU2020218180A1 (en) 2021-08-19
ES2968807T3 (es) 2024-05-14
FI3921030T3 (fi) 2024-01-08
US20240076269A1 (en) 2024-03-07
KR102924196B1 (ko) 2026-02-06
SA521422733B1 (ar) 2024-02-08
RS65040B1 (sr) 2024-02-29
JP2022519744A (ja) 2022-03-24
US11840516B2 (en) 2023-12-12
IL285113A (en) 2021-09-30
SI3921030T1 (sl) 2024-03-29
US12344584B2 (en) 2025-07-01
US20200247752A1 (en) 2020-08-06
AU2020218180B2 (en) 2025-09-04
MX2021009396A (es) 2021-09-10
PL3921030T3 (pl) 2024-05-06
EP3921030B1 (en) 2023-10-11
CA3128975A1 (en) 2020-08-13
SG11202108599SA (en) 2021-09-29
SMT202400003T1 (it) 2024-03-13
DK3921030T3 (da) 2024-01-02
WO2020163268A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
JP7451543B2 (ja) Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体
BR112020025618A2 (pt) piridinila e pirazinil-(aza)indolsulfonamidas
JP5913651B2 (ja) 疼痛および他の疾患の処置のための化合物および方法
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
CA3128975C (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
RU2790174C1 (ru) Производные 1-[[2-(2,2,2-трифторэтокси)пирид-4-ил]метил]мочевины в качестве потенциаторов kcnq
HK40068179B (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
HK40068179A (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
WO2025113692A1 (zh) 磺酰脲衍生物及其应用
CN119997950A (zh) 用于治疗疾病的单羧酸转运蛋白4的杂环抑制剂的盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230203

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240306

R150 Certificate of patent or registration of utility model

Ref document number: 7451543

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150